AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

The motivation behind seeking an answer to the question “Is RNAi of target X likely to induce the same phenotype as a small-molecule inhibitor of target X?” is two-fold. First, in a target ...

The US company also sells a small-molecule HER2 inhibitor – Tukysa (tucatinib) – which is now partnered with Merck & Co outside the US, Canada and Europe as part of a $4.2 billion alliance ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

The recent approval of the dual-inhibitors (EGFR/HER2), such as lapatinib, opens a new avenue for therapeutic strategies with multitargeted drugs, not only directed against the surface receptors ...

As part of Arvinas global collaboration with Pfizer, the companies plan to: Announce topline data for the VERITAC-2 Phase 3 monotherapy cli ...

Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into an additional clinical ...

Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m.

Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.